Surrozen, Inc./DE
Surrozen, Inc. is a U.S.-based biopharmaceutical company focused on discovering and developing antibody-based therapeutics that modulate the Wnt pathway. Its business centers on preclinical and clinical-stage product candidates, research collaborations, and the advancement of its proprietary Wnt therapeutics platform.
Fiscal year 2025 · change from previous year
Development 2020–2025
Business
Share of revenueDiscovery platform used to generate antibody-based therapies that modulate Wnt signaling.
Preclinical and clinical-stage therapeutic candidates derived from the platform.
Milestones, licenses, and other consideration from strategic biotech partnerships.
Research work performed for related parties or collaborators under service arrangements.
Products
Reported · share of revenue- Collaboration and License Revenue93.9 %
- Research Service Revenue6.1 %
Source: 10-K FY2024, revenue the company reports per product line (SEC XBRL). Shares are of the lines shown and add up to 100 %.
Customers
Surrozen does not yet have a commercial customer base for approved products; its current counterparties are collaboration partners, licensors, and related-party research service recipients. If its product candidates are approved in the future, customers would likely include healthcare providers, hospitals, and payors through commercial channels or third-party partners.
Partners that license or co-develop Wnt-based programs and may pay milestones or shared development funding.
Affiliated counterparties that purchase research services while programs remain pre-commercial.
Potential end customers for approved therapies, purchased through hospitals, clinics, and reimbursement systems.
Strategy
Surrozen's strategy is to advance its Wnt therapeutics platform through research, clinical development, and regulatory submissions while preserving optionality for collaborations. The company also relies on third-party manufacturing and may need external commercialization partners if any product candidate is approved.
Clinical and regulatory progress is the main path to future value creation.
Partnerships can provide funding, development support, and commercialization reach.
Biologics development depends on compliant third-party production and scale-up.
Geography
Surrozen is headquartered in the United States, but its development and supply chain are international. The company notes a contract manufacturing organization in the United Kingdom for preclinical materials and supplies, and it also references exposure to international operations and trade policy.
Risks
Surrozen is exposed to the typical risks of an early-stage biopharmaceutical company: clinical failure, regulatory delay, competition, and dependence on external capital. Its business also depends on third-party manufacturers and collaborators, which creates execution risk across development, supply, and future commercialization.
- Clinical and regulatory failureImpact: CriticalLikelihood: Medium
Product candidates may not show sufficient safety or efficacy, or may not gain approval.
Exposure: Wnt therapeutics pipeline
- Need for additional financingImpact: HighLikelihood: High
Development-stage biotech programs require ongoing capital before product revenue exists.
Exposure: Pipeline advancement and corporate operations
- Third-party manufacturing dependenceImpact: HighLikelihood: Medium
The company relies on external manufacturers for preclinical materials and future supply.
Exposure: cGMP production and scale-up
- Competition from larger biotech and pharma companiesImpact: HighLikelihood: Medium
Competitors may develop better or faster therapies and capture market share first.
Exposure: Wnt modulation and related therapeutic areas
- International trade and geopolitical exposureImpact: MediumLikelihood: Low
Foreign manufacturing and operations can be affected by tariffs, sanctions, and disruptions.
Exposure: United Kingdom supply chain and future foreign markets
Accounting
Judgemental itemsMilestones and license fees may be recognized when performance obligations are satisfied, affecting quarter-to-quarter revenue.
Impact: Can cause large swings in reported revenue
Derivative-like financing instruments are remeasured, creating noncash gains or losses.
Impact: Can materially affect net income or loss
Revenue depends on service scope, timing, and counterparty arrangements.
Impact: Affects top-line comparability
Clinical, preclinical, and manufacturing costs require accrual estimates and judgment.
Impact: Affects operating loss and cash burn analysis
Similar listed companies
Publicly listed companies with a comparable business focus.
Provectus Biopharmaceuticals, Inc.
PVCT · Pharmaceutical Preparations
Curanex Pharmaceuticals Inc
CURX · Pharmaceutical Preparations
Curanex Pharmaceuticals Inc is a U.S.-based pharmaceutical preparations company that appears to be in an early-stage, development-focused phase.
Vincerx Pharma, Inc.
Pharmaceutical Preparations
Zura Bio Ltd
ZURA · Biological Products, (No Diagnostic Substances)
Zura Bio Ltd is a U.S.-based clinical-stage biopharmaceutical company focused on developing antibody-based therapies for immune-mediated diseases.
Genprex, Inc.
GNPX · Pharmaceutical Preparations
Ocean Biomedical, Inc.
OCEA · Pharmaceutical Preparations
Last updated: 24/09/2026